Professor Unger (Germany): Until now research has focused on the acute situation. However a few experiments have investigated the long-term consequences and they demonstrate a continued increase in angiotensin II levels, and a decrease in renin levels and plasma renin activity. Therefore, these results do indicate that this elevation of angiotensin II is maintained.
Professor Sever (UK): Dr Miyazaki, I must congratulate you on your very elegant experiments. Do you have any explanation for the site-specific differences found between the femoral and carotid artery in regard to chymase conversion in the dog? And secondly, do you know what happens in the carotid artery in man?
Professor Miyazaki (Japan): In my experiments, both ACE and chymase activities increased in the carotid artery, while ACE, but not chymase, activity increased in the femoral artery. The explanation for these site-specific differences may depend on the extent of injury, although this has not been confirmed. In addition to these differences between the two arteries, there are also differences in the results between arteries and veins. I did not show the data today, but I have performed experiments measuring chymase activity in human graft vessels, the intercostal vein and artery. In this situation, there is a higher chymase concentration in the vein compared to the artery. In addition, neointima formation occurs easily in femoral vein grafts and I think that this is a reason for vein graft disease.
Questioner: Dr Miyazaki, it was very interesting to see the difference between the femoral and carotid artery in terms of chymase expression or chymase response after balloon injury. My question also relates to that raised by Professor Sever, in that I would like to know why there was a clear difference between the two arteries. As far as I am aware, the main cell source of chymase is the muscle cell, and I do not think there is a large difference in the number of muscle cells between the femoral and carotid artery. Therefore, do you have any proposed mechanism to account for the difference in chymase expression between these arteries?
Professor Miyazaki: In normal conditions, I think there is no difference between the chymase expression found in the carotid or femoral artery. However after injury, the results change, and this may depend on the extent of injury or on the thickness, or elasticity of the arteries. The results may also be slightly different depending on at what time they are measured.
Questioner: Was balloon size to artery size controlled in a similar way in both arteries? For instance, did you use a bigger balloon in the carotid artery and a smaller balloon for the femoral artery?
Professor Miyazaki: No, the same size balloon was used.
Questioner: Dr Miyazaki, you reported that ACE inhibitors and angiotensin II antagonists blunted the effect of the balloon injury by approximately 50%. Did you perform any dose-response studies to see whether a higher dose of the angiotensin II antagonist would increase this blunting effect even further? For instance, I think that you need to carry out an experiment using an even higher dose, perhaps 3 to 10 times higher, to really answer whether you have achieved the greatest reduction possible.
Professor Miyazaki: In these experiments I did not investigate the effect of different doses of angiotensin II antagonist. While it is possible to postulate that a higher dose of angiotensin II antagonist will result in an even greater reduction, I think it is important to remember that the dose used in the study was already high.
Questioner: Did you perform any of these balloon injury experiments in a system where the endogenous renin-angiotensin system is markedly suppressed, such as in DOCA-salt hypertension to investigate whether the angiotensin II antagonist still works in this situation?
Professor Miyazaki: No, I did not but that is a good suggestion for future studies.
Professor Brenner (USA): We now have, almost without exception, evidence in humans that ACE inhibitors lower blood pressure. They reduce the incidence of stroke and save hearts, whether you are talking about asymptomatic left ventricular abnormalities or severe congestive heart failure. They also save kidneys. If chymase is the predominant pathway for the conversion of angiotensin I to angiotensin II in humans, why, on the one hand, is there such remarkable protection by ACE inhibitors and why in the studies that have been done to date in humans do we see no particular advantage of angiotensin receptor blockers over ACE inhibitors?
Professor Miyazaki: I also ask myself this same question. That is, why, when my experimental data shows that chymase is so much more important in this pathway, are ACE inhibitors so effective in humans? I cannot answer precisely, but I do have some data that may help to explain this. Perhaps the answer is that the induction of chymase and induction of ACE does not take place at the same time. For example, my study using cardiomyopathic hamsters found only an increase of chymase, but not ACE in the heart. However in the first study we used 25-week-old hamsters, and we then moved on to look at older hamsters. In these older animals we found an increase of ACE activity. Thus, it may be that the angiotensin II-generating system and chymase induction take place at a much earlier stage than ACE. Therefore, when a patient comes to the clinic, it is usually at quite a late stage in their disease and this will relate to the late stage in the animal experiment model. So, in this situation, we can find the increase in ACE and the ACE inhibitor is quite effective. However, in earlier stages of disease, the ACE level is stable and chymase has increased and beginning to produce angiotensin II for tissue remodelling. This is my present hypothesis.
Questioner: I think that chymase appears more slowly in the clinical situation because it is located in the perivascular region, not on the surface of the endothelial cells. Thus, while ACE inhibitors may be effective in the acute situation by reducing angiotensin input into the cardiovascular system, chymase inhibition may follow later. I think it takes time to see the difference and we therefore need longerterm studies to assess differences between the ACE inhibitors and the angiotensin II antagonists. It would also be very useful to develop and evaluate a chymase inhibitor to see how chymase is involved in cardiovascular mortality.
Questioner: Dr Unger, I would like to ask about the insurmountable antagonists. Is this common for all kinds of angiotensin II antagonists, and is this beneficial or sometimes dangerous in clinical applications?
Professor Unger: The action of the antagonists is always reversible, so there is no need to be concerned that the antagonist will never be separated from the receptor. This is actually a good example of how sticking to the receptor can determine the duration of action to a much greater extent than the plasma half-lives of these drugs, which is a lesson we have already learned from the ACE inhibitors. For instance, the action of short-and long-acting ACE inhibitors can be explained by the Ki of the dissociation. There are only two competitive antagonists, iprosartan and losartan and, of these two, losartan actually incorporates features of both, since it is only the active metabolite of this agent which is a competitive antagonist. All of the other angiotensin II receptor antagonists are non-competitive or insurmountable depending on the semantics that you want to use.
Questioner: Dr Ogihara, you showed data for special patient groups; for instance, elderly patients and those with renal incompetence. In your comparison study to enalapril there was a small tendency for transaminases to be higher than candesartan in these patients. Do you also have data on patients with liver cirrhosis or any kind of liver damage?
Professor Ogihara (Japan): I do not have specific data on patients with liver cirrhosis or defects in liver function. This will be further discussed in Session III by Dr Sever.
